Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cannabidiol + tetrahydrocannabinol (Pure Green Pharmaceuticals)
- Development stage
- Phase 3
- Lead developer
- Pure Green Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
Pure Green sublingual tablets are a combination therapy containing cannabidiol (CBD) and tetrahydrocannabinol (THC) developed by Pure Green Pharmaceuticals for the management of pain associated with osteoarthritis of the knee. This small molecule formulation targets the endocannabinoid system, specifically interacting with cannabinoid receptors to modulate pain signaling and inflammatory responses. The product is designed as a water-soluble, rapidly dissolvable sublingual tablet, a route of administration intended to bypass first-pass metabolism, improve bioavailability, and enhance patient compliance. The therapy was evaluated in a Phase 2 open-label clinical trial (NCT04195269) to assess its safety and efficacy in reducing average daily pain scores, as well as its impact on quality of life, sleep, and anxiety in patients with knee osteoarthritis.
- Other names
- Pure Green sublingual tabletsPure Green CBD/THC tabletsPure Green CBD + THC sublingual tablets
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)GPR55 (G protein-coupled receptor 55)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on cannabidiol + tetrahydrocannabinol (Pure Green Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cannabidiol + tetrahydrocannabinol (Pure Green Pharmaceuticals).